HT BioImaging

Executive Summary

HT BioImaging is an Israeli med-tech company developing a patented Heat Diffusion Imaging (HDI) platform for non-invasive, real-time cancer detection. The technology delivers a focused heat pulse to tissue and analyzes the diffusion response using AI-driven signal processing, generating high-resolution probability maps of malignancy. The platform targets multiple human oncology indications (oral, cervical, skin, prostate, colon, intra-operative margin detection) as well as veterinary oncology for subcutaneous and dermal masses in dogs and cats. Founded in 2020 and headquartered in Tel Aviv, the company operates at a preclinical stage with 50-200 employees. Its HDI platform aims to address the critical need for rapid, accurate, and non-invasive cancer screening and margin assessment, potentially reducing reliance on biopsies and improving surgical outcomes. The company is privately held and has not disclosed total funding or valuation, indicating it may be in early growth phases seeking partnerships or regulatory pathways. With its novel approach combining thermal physics and AI, HT BioImaging stands out in the oncology diagnostics space, though it faces typical preclinical development risks including regulatory hurdles, clinical validation, and commercial adoption.

Upcoming Catalysts (preview)

• Q4 2026First-in-human clinical trial initiation for oral cancer detection60% success
• Q2 2027FDA clearance for veterinary HDI platform in dogs and cats70% success
• Q3 2026Series B financing round to fund clinical development80% success